Sozinibercept

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameSozinibercept
Drug Alias NameOPT-302VGX-300
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionVascular endothelial growth factor C inhibitorsVascular endothelial growth factor D inhibitors
TargetsVascular endothelial growth factor CVascular endothelial growth factor D
Therapy Area/IndicationsDiabetic macular oedemaNeovascularization, PathologicMacular Degeneration +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[33] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOrphan Europe Sarl
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOpthea Ltd
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaNeovascularization, PathologicMacular Degeneration +[6] 

Other Information

ATC CodeN/A
Related LinksN/A